about
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tractNeuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in miceChinese herbal medicines in the treatment of IBD and colorectal cancer: a review.Experimental colitis in mice is attenuated by topical administration of chlorogenic acid.Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice.Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in miceEndocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract.Nociceptin / orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases.Role of transient receptor potential channels in intestinal inflammation and visceral pain: novel targets in inflammatory bowel diseases.T cell-activated signaling pathways and locally produced cytokines as potential targets in celiac disease.Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis.Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases.Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms
P50
Q28302731-5C19FCDD-F614-42E7-9DA0-10107C86D1FBQ28834404-DB1B75A7-D570-492B-B440-0EEC09CE4485Q34100569-5382DC7E-04E6-4063-B6C2-E65736A5A862Q35626127-1430650B-8E25-4CE4-B1E3-76DBE1B4C183Q36772909-893D4647-AEDA-4681-A492-8EA8A38C1172Q37340687-2B5ED595-BEEB-4E59-A4DE-3362106614FAQ37416662-4A12EB21-303B-4061-AB9F-E0BFF5829B7FQ37491434-C91ABC1A-0A5E-4643-9528-C92F09C649C1Q38097256-6287CAAF-E96E-4E12-BB41-A3F17AD11529Q38114955-484F2F40-D5F2-4425-AC43-4FABFC11E7DBQ38273302-B54F4BDF-E728-4DBB-A320-D0E61B2E7F9DQ38367531-73C3E3A2-F8C5-4DFC-97AC-380D1ACCC4F3Q38795301-55E43BF9-1F8D-4DF7-AB2A-F8350F3987F8Q39140866-2A38F002-2910-429C-95F5-A8CA14A25862Q39194989-8084EA9A-A83E-4645-9A7E-4A5519EA15C1
P50
description
onderzoeker
@nl
name
Maciej Sałaga
@ast
Maciej Sałaga
@en
Maciej Sałaga
@es
Maciej Sałaga
@nl
Maciej Sałaga
@sl
type
label
Maciej Sałaga
@ast
Maciej Sałaga
@en
Maciej Sałaga
@es
Maciej Sałaga
@nl
Maciej Sałaga
@sl
prefLabel
Maciej Sałaga
@ast
Maciej Sałaga
@en
Maciej Sałaga
@es
Maciej Sałaga
@nl
Maciej Sałaga
@sl
P106
P21
P214
255144647688919992469
P31
P735
P7859
viaf-255144647688919992469